Industry
Biotechnology
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 10:01 am
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 3:27 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 8:06 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 11:16 am
Portfolio Pulse from Benzinga Newsdesk
April 02, 2024 | 12:46 pm
Portfolio Pulse from Benzinga Newsdesk
April 02, 2024 | 11:11 am
Portfolio Pulse from dijoy@benzinga.com
March 21, 2024 | 11:03 am
Portfolio Pulse from Benzinga Insights
March 21, 2024 | 10:15 am
Portfolio Pulse from Benzinga Insights
March 20, 2024 | 3:01 pm
Portfolio Pulse from Avi Kapoor
February 08, 2024 | 6:07 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.